Unknown

Dataset Information

0

Cytokines as Biomarkers of Treatment Response to IFN ? in Relapsing-Remitting Multiple Sclerosis.


ABSTRACT: Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable. Objective. To find a biomarker for treatment response to IFN? among pro- and anti-inflammatory cytokines. Materials and Methods. IFN-?, TNF-?, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-?1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFN? treatment and were divided into good responders (GR, n = 19) and poor responders (PR, n = 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx). Results. GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN-?, TNF-?, and IL-2 than noRx. PR had significantly higher IFN-? serum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF-?1 or the levels of all cytokines measured in CSF between the 3 groups of patients. Conclusions. Baseline serum levels of IL-17A can be used as a biomarker of IFN? treatment response.

SUBMITTER: Dimisianos N 

PROVIDER: S-EPMC4134814 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis.

Dimisianos Nikolaos N   Rodi Maria M   Kalavrizioti Dimitra D   Georgiou Vasileios V   Papathanasopoulos Panagiotis P   Mouzaki Athanasia A  

Multiple sclerosis international 20140722


Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable. Objective. To find a biomarker for treatment response to IFNβ among pro- and anti-inflammatory cytokines. Materials and Methods. IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-β1 levels were measured in serum  ...[more]

Similar Datasets

| S-EPMC3503813 | biostudies-literature
| S-EPMC5794695 | biostudies-other
2020-02-10 | GSE126427 | GEO
| S-EPMC3699254 | biostudies-other
| S-EPMC10401910 | biostudies-literature
| S-EPMC2276246 | biostudies-literature
| S-EPMC6580020 | biostudies-literature
| S-EPMC6513682 | biostudies-literature
2015-03-10 | GSE66573 | GEO
| S-EPMC7730283 | biostudies-literature